ClinicalTrials.gg
CompletedNCT05382312Updated Jun 17, 2026Results posted

Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis

A Phase 2 interventional study of GSK3036656 and Bedaquiline in Tuberculosis, sponsored by GlaxoSmithKline. Completed at 1 site in South Africa. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-17.

Primary conditionTuberculosis, PulmonaryRegistry: TuberculosisReclassifiedWhy we changed it
Registry
Tuberculosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Tuberculosis, Pulmonary
Why
  1. The study's title name Tuberculosis, Pulmonary, a narrower term within Tuberculosis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing bedaquiline in Tuberculosis, Pulmonary — 5 open to participants now, 8 under way, 5 of them phase 3. bedaquiline · Tuberculosis, Pulmonary.

Enrollment
13th of 22
127 · median 235
Started
2022
with 1 other
Phase 2
10 of 22
2 open now
Registered
13th of 22
by date
Lead sponsor
1 of 22
GlaxoSmithKline

Among the 22 studies testing bedaquiline in Tuberculosis, Pulmonary, this one is the 13th largest by enrollment, is one of 2 that started in 2022, is one of 10 in phase 2, and was the 13th registered.

Tuberculosis, Pulmonary

319 studies on the registry are indexed under Tuberculosis, Pulmonary; 71 are open to participants now.

Browse Tuberculosis, Pulmonary studies →

Open to participants now

5 of the 22 studies testing bedaquiline in Tuberculosis, Pulmonary are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About bedaquiline

bedaquiline: first FDA approval 2012 (SIRTURO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Tuberculosis, Pulmonary studies recruiting now, 22 (48%) set no upper age limit and 20 (43%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing bedaquiline in Tuberculosis, Pulmonary, or all of them as a file.
02

Study summary

This study measured the early bactericidal activity (EBA), safety, tolerability and pharmacokinetics of GSK3036656 in combination with either delamanid, bedaquiline or BTZ-043 and delamanid in combination with bedaquiline or standard of care, for 14 days, in participants with newly diagnosed sputum smear positive drug-sensitive pulmonary tuberculosis. Participants reverted to the standard treatment (RIFAFOUR e-275) once the study treatment (Day 1 to Day 14) was completed.

03

Conditions studied

  • Tuberculosis

Browse trials for

Keywords

  • Early bactericidal activity
  • Pulmonary tuberculosis
  • RIFAFOUR
  • Bedaquiline
  • Delamanid
  • GSK3036656
  • BTZ-043
04

In context

Tuberculosis, Pulmonary Reclassified

319 studies on the registry are indexed under Tuberculosis, Pulmonary; 71 are open to participants now.

This study's enrollment of 127 is below the median of 146 across 227 interventional studies indexed under Tuberculosis, Pulmonary.

Browse Tuberculosis, Pulmonary studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Tuberculosis, Pulmonary, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Tuberculosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants were 18 to 65 years of age inclusive, at the time of signing the .
  • Participants had:

    1. A new episode of untreated, rifampicin-susceptible pulmonary tuberculosis (TB)
    2. A chest X-ray picture consistent with pulmonary TB
    3. At least one sputum sample positive on direct microscopy for acid-fast bacilli (at least 1+ on the International Union Against Tuberculosis and Lung Disease [IUATLD]/World Health Organization [WHO] scale) or positive on a molecular test (at least medium positive for MTB on Xpert MTB/Rif)
    4. A normal echocardiogram, or an echocardiogram with normal left ventricular function with at most trace to mild valvular regurgitation, and no valvular stenosis
    5. A greater than or equal to (>=) 90 mL/minute (Cockcroft-Gault formula)
  • Male participants were eligible to participate if they agreed to barrier precautions until 90 days after the last dose.
  • A female participant was eligible to participate if she was not pregnant or breastfeeding and was a woman of non- (WONCBP) or a woman of childbearing potential (WOCBP) using a highly effective method. A WOCBP had to have a negative urine or serum pregnancy test, as required by local regulations, before the first dose of study intervention. Only participants who were at least 25 years of age, and females of non-childbearing potential, were eligible for the positron emission tomography-computed tomography (PET-CT) assessments.
  • Participants were capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • There was evidence of a condition or abnormality (as judged by the Investigator) (other than the indication being studied) that might have compromised safety or the interpretation of trial efficacy or safety endpoints.
  • There was clinically significant evidence of extrathoracic TB, as judged by the Investigator.
  • corrected for heart rate by Fridericia's formula (QTcF) was greater than (>) 450 milliseconds (msec).
  • There was arterial hypertension with systolic BP >=160 mm Hg or diastolic BP >=100 mm Hg. Participants with well-controlled hypertension could be included if they were using amlodipine for the duration of the study.
  • Participants had vitiligo.
  • Participants were receiving QT-prolonging drugs, including but not limited to fluoroquinolones, macrolides, and clofazimine.
  • -infected participants who:

    1. had a cluster of differentiation (CD)4+ count \<350 cells/microliters;
    2. had received antiretroviral therapy medication within the last 30 days;
    3. had received oral or intravenous antifungal medication within the last 30 days;
    4. or had an acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection or in the last 12 months (except pulmonary TB).
  • surface antigen (HBsAg) was present, or the antibody test result at screening was positive.
  • Participants had diabetes (Type 1 or 2), point-of-care (HbA1c) above 6.5%, or random glucose over 11.1 millimoles (mmol)/L.
  • There were diseases or conditions in which the use of delamanid or bedaquiline was .
  • Participants had abnormal laboratory values at screening, as graded by the enhanced (CTCAE version 5, 2017).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

06

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    GSK3036656 + Bedaquiline

    Participants received GSK3036656 20 milligram (mg) + bedaquiline 400 mg once daily for 14 days; loading doses: 50 mg GSK3036656 (Day 1), 700 mg bedaquiline (Day 1), 500 mg (Day 2), then 400 mg daily (Days 3-14).

    Drug: GSK3036656 · Drug: Bedaquiline

  • Experimental
    GSK3036656 + Delamanid

    Participants received GSK3036656 20 mg + delamanid 300 mg once daily for 14 days; 50 mg GSK3036656 loading dose on Day 1.

    Drug: GSK3036656 · Drug: Delamanid

  • Experimental
    Delamanid + Bedaquiline

    Participants received delamanid 300 mg + bedaquiline 400 mg once daily for 14 days; bedaquiline loading doses: 700 mg (Day 1), 500 mg (Day 2), then 400 mg daily (Days 3-14).

    Drug: Bedaquiline · Drug: Delamanid

  • Experimental
    Standard of care for drug-sensitive tuberculosis (DS - TB)_Cohort 1

    Participants received Rifafour e-275 (or equivalent generic) once daily for 14 days.

    Drug: RIFAFOUR e-275

  • Experimental
    GSK3036656 + BTZ-043

    Participants received GSK3036656 20 mg + BTZ-043 1000 mg once daily for 14 days; 50 mg GSK3036656 loading dose on Day 1.

    Drug: GSK3036656 · Drug: BTZ-043

  • Experimental
    Standard of care for DS - TB_Cohort 2

    Participants received Rifafour e-275 (or equivalent generic) once daily for 14 days.

    Drug: RIFAFOUR e-275

  • Experimental
    GSK3036656 + Pretomanid

    Participants received GSK3036656 20 mg + pretomanid 200 mg once daily for 14 days; 50 mg GSK3036656 loading dose on Day 1.

    Drug: GSK3036656 · Drug: Pretomanid

  • Experimental
    GSK3036656 + Linezolid

    Participants received GSK3036656 20 mg + linezolid 600 mg once daily for 14 days; 50 mg GSK3036656 loading dose on Day 1.

    Drug: GSK3036656 · Drug: Linezolid

  • Experimental
    GSK3036656 + moxifloxacin

    Participants received GSK3036656 20 mg + moxifloxacin 400 mg once daily for 14 days; 50 mg GSK3036656 loading dose on Day 1.

    Drug: GSK3036656 · Drug: Moxifloxacin

  • Experimental
    Standard of care for DS TB_Cohort 3

    Participants received Rifafour e-275 (or equivalent generic) once daily for 14 days.

    Drug: RIFAFOUR e-275

Interventions

07

What researchers measure

Primary outcomes

  1. Change From Baseline in log10 Colony Forming Units (CFU) of Mycobacterium Tuberculosis (MTB)

    Baseline was defined as the mean of Day -2 and Day -1. If data was available at only one of these timepoints, then that value was used as baseline.

    Time frame: At Baseline and at days 1, 2, 3, 4, 6, 8, 10, 12 and 14

Secondary outcomes

  1. Change From Baseline in Time to Sputum Culture Positivity

    Baseline was defined as the mean of Day -2 and Day -1. If data was available at only one of these timepoints, then that value was used as baseline.

    Time frame: At Baseline and at days 1, 2, 3, 4, 6, 8, 10, 12 and 14

  2. Number of Participants With Serious Adverse Events (SAEs)

    An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, caused a congenital anomaly/birth defect, or was any other situation identified according to medical or scientific judgment.

    Time frame: From Day 1 to Day 28

  3. Number of Participants With Adverse Events (AE) of Grade 3 Severity or Higher

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not it was considered related to the study intervention. The intensity of AEs was assessed using the Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria Version 2.1, where grades were defined based on numeric criteria as follows: Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: potentially life-threatening; Grade 5: death. A higher grade indicated greater severity. Any = occurrence of the event regardless of intensity grade.

    Time frame: From Day 1 to Day 28

  4. Number of Participants With Adverse Events Related to Study Treatment

    Time frame: From Day 1 to Day 28

  5. Number of Participants Withdrawn From the Treatment Due to Adverse Events

    Time frame: From Day 1 to Day 28

  6. Number of Participants Withdrawn From the Study Due to Adverse Events

    Time frame: From Day 1 to Day 28

  7. Number of Participants With Electrocardiogram (ECG) Values of Potential Clinical Importance (PCI)

    PCI ECG values were defined as any ECG findings which, in the opinion of the investigator or medical monitor, would have interfered with the safety of the individual participant. The ECG measurements analyzed were PR Interval, QRS Duration, and QTcF Interval. A value was reported as "high" for a period if it had shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it had shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it had remained unchanged (e.g., High to High), or as "To W/in Range" if it had been within range.

    Time frame: From Day 1 to Day 28

  8. Number of Participants With Hematology Laboratory Values of PCI

    The analyzed hematology parameters were hematocrits, hemoglobin, lymphocytes, neutrophils, and platelets. A value was reported as "high" for a period if it had shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it had shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it had remained unchanged (e.g., High to High), or as "To W/in Range" if it had been within range.

    Time frame: From Day 1 to Day 28

  9. Number of Participants With Clinical Chemistry Laboratory Values of PCI

    The chemistry parameters analyzed were glucose, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, calcium, creatinine, potassium, and sodium. A value was reported as "high" for a period if it had shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it had shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it had remained unchanged (e.g., High to High), or as "To W/in Range" if it had been within range.

    Time frame: From Day 1 to Day 28

  10. Number of Participants With Vital Signs of PCI

    The analyzed vital signs were systolic blood pressure, diastolic blood pressure, pulse rate. A value was reported as "high" for a period if it had shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it had shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it had remained unchanged (e.g., High to High), or as "To W/in Range" if it had been within range.

    Time frame: From Day 1 to Day 28

08

Results

Posted Jun 17, 2026

Participant flow

Participant flow — Overall Study
MilestoneStandard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1GSK3036656 + BedaquilineGSK3036656 + DelamanidDelamanid + BedaquilineGSK3036656 + BTZ-043Standard of Care for DS - TB_Cohort 2GSK3036656 + PretomanidGSK3036656 + LinezolidGSK3036656 + MoxifloxacinStandard of Care for DS TB_Cohort 3
Started914151614316131411
Completed914151613316121310
Not completed0000100111
Withdrew: Adverse event0000000100
Withdrew: Lost to follow-up0000100001
Withdrew: Participant reached protocol-defined stopping criteria0000000010

Outcome measures

PrimaryChange From Baseline in log10 Colony Forming Units (CFU) of Mycobacterium Tuberculosis (MTB)

Baseline was defined as the mean of Day -2 and Day -1. If data was available at only one of these timepoints, then that value was used as baseline.

Time frame:
At Baseline and at days 1, 2, 3, 4, 6, 8, 10, 12 and 14
Reported as:
Mean · log10 CFU/milliliter (mL)
Change From Baseline in log10 Colony Forming Units (CFU) of Mycobacterium Tuberculosis (MTB)
log10 CFU/milliliter (mL)Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1GSK3036656 + BedaquilineGSK3036656 + DelamanidDelamanid + BedaquilineGSK3036656 + BTZ-043Standard of Care for DS-TB_Cohort 2GSK3036656 + PretomanidGSK3036656 + LinezolidGSK3036656 + MoxifloxacinStandard of Care for DS TB_Cohort 3
Baseline6.960 ± 1.10386.441 ± 1.00536.387 ± 0.98816.285 ± 0.75996.457 ± 1.08196.280 ± 1.10456.522 ± 0.71096.691 ± 0.64206.407 ± 0.46226.583 ± 0.5514
Day 1-0.876 ± 0.7375-0.323 ± 0.60140.095 ± 0.4192-0.161 ± 0.48190.028 ± 0.3848-0.369 ± 0.3031-0.002 ± 0.5514-0.150 ± 0.3617-0.598 ± 1.0102-0.218 ± 0.7681
Day 2-1.524 ± 0.5358-0.251 ± 0.6749-0.431 ± 1.2250-0.465 ± 0.8544-0.186 ± 0.6269-0.638 ± 0.4670-0.218 ± 0.7824-0.485 ± 0.7596-0.490 ± 0.3233-1.137 ± 0.3824
Day 3-1.995 ± 1.0519-0.314 ± 0.7666-0.525 ± 0.4308-0.393 ± 0.7996-0.316 ± 0.5088-1.000 ± 0.4217-0.453 ± 0.6354-0.445 ± 0.6234-1.096 ± 0.9501-1.196 ± 0.6813
Day 4-1.961 ± 0.6269-0.749 ± 0.6991-0.559 ± 0.9640-0.302 ± 0.8803-0.637 ± 0.5462-1.236 ± 0.6097-0.541 ± 0.6851-0.961 ± 0.7454-0.870 ± 0.5350-1.691 ± 0.0215
Day 6-1.792 ± 0.2695-0.908 ± 1.0062-1.192 ± 0.6726-0.686 ± 0.8380-0.675 ± 0.8099-1.698 ± 0.8456-0.696 ± 0.6876-1.185 ± 0.5339-1.669 ± 1.3719-1.655 ± 1.0045
Day 8-2.123 ± 0.9417-1.405 ± 0.6347-1.417 ± 0.8551-0.759 ± 0.8265-1.004 ± 0.7408-2.061 ± 1.0022-1.186 ± 0.5268-1.502 ± 0.4553-1.346 ± 0.5983-1.867 ± 0.8490
Day 10-2.642 ± 0.4140-1.143 ± 0.8303-1.568 ± 0.7239-0.679 ± 0.7169-1.137 ± 0.6753-2.289 ± 1.9110-1.187 ± 0.7832-1.427 ± 0.8659-1.145 ± 0.5550-1.708 ± 1.2044
Day 12-2.533 ± 0.5351-1.242 ± 1.0717-1.461 ± 0.5713-1.171 ± 1.0695-1.528 ± 1.1315-2.278 ± 1.7579-1.286 ± 0.5819-1.726 ± 0.8580-1.701 ± 0.9422-2.340 ± 1.4691
Day 14-2.784 ± 0.6634-1.088 ± 0.5239-1.845 ± 0.7738-0.684 ± 1.1807-1.478 ± 0.8847-1.001 ± 1.2730-1.676 ± 0.7156-2.164 ± 1.4641-1.782 ± 0.7243-2.312 ± 1.2667
SecondaryChange From Baseline in Time to Sputum Culture Positivity

Baseline was defined as the mean of Day -2 and Day -1. If data was available at only one of these timepoints, then that value was used as baseline.

Time frame:
At Baseline and at days 1, 2, 3, 4, 6, 8, 10, 12 and 14
Reported as:
Mean · log10 hours
Change From Baseline in Time to Sputum Culture Positivity
log10 hoursStandard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1GSK3036656 + BedaquilineGSK3036656 + DelamanidDelamanid + BedaquilineGSK3036656 + BTZ-043Standard of Care for DS - TB_Cohort 2GSK3036656 + PretomanidGSK3036656 + LinezolidGSK3036656 + MoxifloxacinStandard of Care for DS TB_Cohort 3
Baseline1.987 ± 0.13502.016 ± 0.12532.039 ± 0.13162.057 ± 0.09472.077 ± 0.17132.079 ± 0.11442.000 ± 0.09362.002 ± 0.07982.023 ± 0.08192.002 ± 0.1120
Day 10.143 ± 0.08680.077 ± 0.07990.009 ± 0.05250.037 ± 0.0505-0.004 ± 0.09890.098 ± 0.07160.010 ± 0.03940.030 ± 0.04720.079 ± 0.08470.082 ± 0.0749
Day 20.243 ± 0.04870.172 ± 0.06370.096 ± 0.07000.089 ± 0.06140.041 ± 0.09720.167 ± 0.05280.089 ± 0.08940.078 ± 0.07310.139 ± 0.07610.199 ± 0.0975
Day 30.266 ± 0.07060.222 ± 0.07570.129 ± 0.06900.170 ± 0.18780.053 ± 0.06760.197 ± 0.02980.122 ± 0.07300.121 ± 0.06860.153 ± 0.05740.212 ± 0.1004
Day 40.320 ± 0.08470.234 ± 0.05840.182 ± 0.06850.142 ± 0.06160.093 ± 0.10090.232 ± 0.08950.160 ± 0.05440.140 ± 0.06340.181 ± 0.09550.211 ± 0.1102
Day 60.344 ± 0.10120.295 ± 0.10630.234 ± 0.06650.165 ± 0.09190.125 ± 0.10050.302 ± 0.06540.187 ± 0.04860.183 ± 0.09900.237 ± 0.17910.289 ± 0.1049
Day 80.364 ± 0.14250.327 ± 0.10440.234 ± 0.11650.236 ± 0.19150.180 ± 0.09670.210 ± 0.31650.215 ± 0.07720.251 ± 0.07790.267 ± 0.10730.340 ± 0.0968
Day 100.401 ± 0.09510.367 ± 0.10110.279 ± 0.07490.223 ± 0.06490.215 ± 0.11190.299 ± 0.23480.276 ± 0.07220.242 ± 0.09760.286 ± 0.09510.292 ± 0.1206
Day 120.361 ± 0.04240.389 ± 0.13440.294 ± 0.07480.290 ± 0.14590.232 ± 0.09070.337 ± 0.16600.287 ± 0.07080.317 ± 0.09910.251 ± 0.15460.355 ± 0.1764
Day 140.434 ± 0.07140.376 ± 0.09380.328 ± 0.10190.330 ± 0.17730.273 ± 0.12960.258 ± 0.05910.344 ± 0.07290.267 ± 0.09550.323 ± 0.10450.362 ± 0.1319
SecondaryNumber of Participants With Serious Adverse Events (SAEs)

An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, caused a congenital anomaly/birth defect, or was any other situation identified according to medical or scientific judgment.

Time frame:
From Day 1 to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsStandard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1GSK3036656 + BedaquilineGSK3036656 + DelamanidDelamanid + BedaquilineGSK3036656 + BTZ-043Standard of Care for DS - TB_Cohort 2GSK3036656 + PretomanidGSK3036656 + LinezolidGSK3036656 + MoxifloxacinStandard of Care for DS - TB_Cohort 3
Number of Participants With Serious Adverse Events (SAEs)0000000100
SecondaryNumber of Participants With Adverse Events (AE) of Grade 3 Severity or Higher

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not it was considered related to the study intervention. The intensity of AEs was assessed using the Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria Version 2.1, where grades were defined based on numeric criteria as follows: Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: potentially life-threatening; Grade 5: death. A higher grade indicated greater severity. Any = occurrence of the event regardless of intensity grade.

Time frame:
From Day 1 to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AE) of Grade 3 Severity or Higher
ParticipantsStandard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1GSK3036656 + BedaquilineGSK3036656 + DelamanidDelamanid + BedaquilineGSK3036656 + BTZ-043Standard of Care for DS - TB_Cohort 2GSK3036656 + PretomanidGSK3036656 + LinezolidGSK3036656 + MoxifloxacinStandard of Care for DS - TB_Cohort 3
Grade 30000101100
Grade 40000000000
Grade 50000000000
SecondaryNumber of Participants With Adverse Events Related to Study Treatment
Time frame:
From Day 1 to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Related to Study Treatment
ParticipantsStandard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1GSK3036656 + BedaquilineGSK3036656 + DelamanidDelamanid + BedaquilineGSK3036656 + BTZ-043Standard of Care for DS - TB_Cohort 2GSK3036656 + PretomanidGSK3036656 + LinezolidGSK3036656 + MoxifloxacinStandard of Care for DS - TB_Cohort 3
Number of Participants With Adverse Events Related to Study Treatment5456713476
SecondaryNumber of Participants Withdrawn From the Treatment Due to Adverse Events
Time frame:
From Day 1 to Day 28
Reported as:
Count of participants · Participants
Number of Participants Withdrawn From the Treatment Due to Adverse Events
ParticipantsStandard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1GSK3036656 + BedaquilineGSK3036656 + DelamanidDelamanid + BedaquilineGSK3036656 + BTZ-043Standard of Care for DS TB_Cohort 2GSK3036656 + PretomanidGSK3036656 + LinezolidGSK3036656 + MoxifloxacinStandard of Care for DS TB_Coohrt 3
Number of Participants Withdrawn From the Treatment Due to Adverse Events0000001200
SecondaryNumber of Participants Withdrawn From the Study Due to Adverse Events
Time frame:
From Day 1 to Day 28
Reported as:
Count of participants · Participants
Number of Participants Withdrawn From the Study Due to Adverse Events
ParticipantsStandard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1GSK3036656 + BedaquilineGSK3036656 + DelamanidDelamanid + BedaquilineGSK3036656 + BTZ-043Standard of Care for DS TB_Cohort 2GSK3036656 + PretomanidGSK3036656 + LinezolidGSK3036656 + MoxifloxacinStandard of Care for DS TB_Cohort 3
Number of Participants Withdrawn From the Study Due to Adverse Events0000000100
SecondaryNumber of Participants With Electrocardiogram (ECG) Values of Potential Clinical Importance (PCI)

PCI ECG values were defined as any ECG findings which, in the opinion of the investigator or medical monitor, would have interfered with the safety of the individual participant. The ECG measurements analyzed were PR Interval, QRS Duration, and QTcF Interval. A value was reported as "high" for a period if it had shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it had shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it had remained unchanged (e.g., High to High), or as "To W/in Range" if it had been within range.

Time frame:
From Day 1 to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Values of Potential Clinical Importance (PCI)
ParticipantsStandard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1GSK3036656 + BedaquilineGSK3036656 + DelamanidDelamanid + BedaquilineGSK3036656 + BTZ-043Standard of Care for DS TB_Cohort 2GSK3036656 + PretomanidGSK3036656 + LinezolidGSK3036656 + MoxifloxacinStandard of Care for DS TB_Cohort 3
PR Interval, To Low0000000000
PR Interval, To W/in Range or No Change913151614316131211
PR Interval, To High0100000020
QRS Duration, To Low0000000000
QRS Duration, To W/in Range or No Change914141614316131311
QRS Duration, To High0010000010
QTcF Interval, To Low0000000000
QTcF Interval, To W/in Range or No Change914131414315111411
QTcF Interval, To High0022001200
SecondaryNumber of Participants With Hematology Laboratory Values of PCI

The analyzed hematology parameters were hematocrits, hemoglobin, lymphocytes, neutrophils, and platelets. A value was reported as "high" for a period if it had shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it had shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it had remained unchanged (e.g., High to High), or as "To W/in Range" if it had been within range.

Time frame:
From Day 1 to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Hematology Laboratory Values of PCI
ParticipantsStandard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1GSK3036656 + BedaquilineGSK3036656 + DelamanidDelamanid + BedaquilineGSK3036656 + BTZ-043Standard of Care for DS TB_Cohort 2GSK3036656 + PretomanidGSK3036656 + LinezolidGSK3036656 + MoxifloxacinStandard of Care for DS TB_Cohort 3
Hematocrit, To Low0001000000
Hematocrit, To W/in Range or No Change914151514316131411
Hematocrit, To High0000000000
Hemoglobin, To Low0010000000
Hemoglobin, To W/in Range or No Change914141614316131411
Hemoglobin, To High0000000000
Lymphocytes, To Low0010101200
Lymphocytes, To W/in Range or No Change914141613315111411
Lymphocytes, To High0000000000
Neutrophils, To Low0010000000
Neutrophils, To W/in Range or No Change914141614316131411
Neutrophils, To High0000000000
Platelets, To Low0000000000
Platelets, To W/in Range or No Change814121212313101311
Platelets, To High1034203310
SecondaryNumber of Participants With Clinical Chemistry Laboratory Values of PCI

The chemistry parameters analyzed were glucose, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, calcium, creatinine, potassium, and sodium. A value was reported as "high" for a period if it had shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it had shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it had remained unchanged (e.g., High to High), or as "To W/in Range" if it had been within range.

Time frame:
From Day 1 to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Clinical Chemistry Laboratory Values of PCI
ParticipantsStandard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1GSK3036656 + BedaquilineGSK3036656 + DelamanidDelamanid + BedaquilineGSK3036656 + BTZ-043Standard of Care for DS - TB_Cohort 2GSK3036656 + PretomanidGSK3036656 + LinezolidGSK3036656 + MoxifloxacinStandard of Care for DS - TB_Cohort 3
Glucose, To Low1000000100
Glucose, To W/in Range or No Change814151614315121411
Glucose, To High0000001000
ALT, To Low0000000000
ALT, To W/in Range or No Change914141614315131211
ALT, To High0010001020
AST, To Low0000000000
AST, To W/in Range or No Change914151614316121411
AST, To High0000000100
Bilirubin, To Low0000000000
Bilirubin, To W/in Range or No Change914151614316131411
Bilirubin, To High0000000000
Calcium, To Low0100000000
Calcium, To W/in Range or No Change913151614316131411
Calcium, To High0000000000
Creatinine, To Low0000000000
Creatinine, To W/in Range or No Change814131611215121410
Creatinine, To High1020311101
Potassium, To Low0000000000
Potassium, To W/in Range or No Change813131312314111311
Potassium, To High1123202210
Sodium, To Low0000000000
Sodium, To W/in Range or No Change914151614316131411
Sodium, To High0000000000
SecondaryNumber of Participants With Vital Signs of PCI

The analyzed vital signs were systolic blood pressure, diastolic blood pressure, pulse rate. A value was reported as "high" for a period if it had shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it had shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it had remained unchanged (e.g., High to High), or as "To W/in Range" if it had been within range.

Time frame:
From Day 1 to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs of PCI
ParticipantsStandard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1GSK3036656 + BedaquilineGSK3036656 + DelamanidDelamanid + BedaquilineGSK3036656 + BTZ-043Standard of Care for DS - TB_Cohort 2GSK3036656 + PretomanidGSK3036656 + LinezolidGSK3036656 + MoxifloxacinStandard of Care for DS TB_Cohort 3
Systolic Blood Pressure, To Low0000000000
Systolic Blood Pressure, To W/in Range or No Change914151614316131411
Systolic Blood Pressure, To High0000000000
Diastolic Blood Pressure, To Low0000100000
Diastolic Blood Pressure, To W/in Range or No Change914151612316131411
Diastolic Blood Pressure, To High0000100000
Pulse Rate, To Low0000000000
Pulse Rate, To W/in Range or No Change91414159316121210
Pulse Rate, To High0011500121

Adverse events

Collected over Adverse events and serious AEs were reported from Day 1 to Day 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 10/9 (0%)0/9 (0%)9/9 (100%)
GSK3036656 + Bedaquiline0/14 (0%)0/14 (0%)11/14 (78.6%)
GSK3036656 + Delamanid0/15 (0%)0/15 (0%)10/15 (66.7%)
Delamanid + Bedaquiline0/16 (0%)0/16 (0%)12/16 (75%)
GSK3036656 + BTZ-0430/14 (0%)0/14 (0%)11/14 (78.6%)
Standard of Care for DS - TB_Cohort 20/3 (0%)0/3 (0%)1/3 (33.3%)
GSK3036656 + Pretomanid0/16 (0%)0/16 (0%)12/16 (75%)
GSK3036656 + Linezolid0/13 (0%)1/13 (7.7%)8/13 (61.5%)
GSK3036656 + Moxifloxacin0/14 (0%)0/14 (0%)11/14 (78.6%)
Standard of Care for DS TB_Cohort 30/11 (0%)0/11 (0%)9/11 (81.8%)
Most frequent serious events
Most frequent serious events
EventStandard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1GSK3036656 + BedaquilineGSK3036656 + DelamanidDelamanid + BedaquilineGSK3036656 + BTZ-043Standard of Care for DS - TB_Cohort 2GSK3036656 + PretomanidGSK3036656 + LinezolidGSK3036656 + MoxifloxacinStandard of Care for DS TB_Cohort 3
SeizureNervous system disorders0/90/140/150/160/140/30/161/130/140/11
Most frequent other events
Showing 10 of 80
Most frequent other events
EventStandard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1GSK3036656 + BedaquilineGSK3036656 + DelamanidDelamanid + BedaquilineGSK3036656 + BTZ-043Standard of Care for DS - TB_Cohort 2GSK3036656 + PretomanidGSK3036656 + LinezolidGSK3036656 + MoxifloxacinStandard of Care for DS TB_Cohort 3
PruritusSkin and subcutaneous tissue disorders4/92/141/154/161/141/30/161/130/142/11
Abdominal painGastrointestinal disorders0/91/140/150/160/141/31/160/131/140/11
Neck painMusculoskeletal and connective tissue disorders0/90/140/150/160/141/30/160/130/140/11
HeadacheNervous system disorders3/92/140/152/163/140/30/160/130/141/11
HaemoptysisRespiratory, thoracic and mediastinal disorders2/91/141/150/160/141/32/160/131/141/11
Rash pruriticSkin and subcutaneous tissue disorders1/91/142/150/160/141/31/160/130/142/11
NauseaGastrointestinal disorders2/93/143/152/162/140/31/162/131/141/11
Back painMusculoskeletal and connective tissue disorders2/90/143/152/162/140/30/160/131/140/11
Gamma-glutamyltransferase increasedInvestigations0/90/140/150/160/140/31/160/133/140/11
DizzinessNervous system disorders0/90/140/152/163/140/30/160/132/141/11

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1GSK3036656 + BedaquilineGSK3036656 + DelamanidDelamanid + BedaquilineGSK3036656 + BTZ-043Standard of Care for DS - TB_Cohort 2GSK3036656 + PretomanidGSK3036656 + LinezolidGSK3036656 + MoxifloxacinStandard of Care for DS TB_Cohort 3Total
Mean33.3 ± 7.7931.5 ± 8.7032.9 ± 9.0133.1 ± 7.4933.9 ± 7.3746.3 ± 10.1235.4 ± 11.0236.1 ± 12.1531.6 ± 7.8034.6 ± 11.3333.9 ± 9.32
Sex: Female, Male
Sex: Female, Male(Participants)Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1GSK3036656 + BedaquilineGSK3036656 + DelamanidDelamanid + BedaquilineGSK3036656 + BTZ-043Standard of Care for DS - TB_Cohort 2GSK3036656 + PretomanidGSK3036656 + LinezolidGSK3036656 + MoxifloxacinStandard of Care for DS TB_Cohort 3Total
Female121300112213
Male81214131431512129112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Standard of Care for Drug-sensitive Tuberculosis (DS - TB)_Cohort 1GSK3036656 + BedaquilineGSK3036656 + DelamanidDelamanid + BedaquilineGSK3036656 + BTZ-043Standard of Care for DS - TB_Cohort 2GSK3036656 + PretomanidGSK3036656 + LinezolidGSK3036656 + MoxifloxacinStandard of Care for DS TB_Cohort 3Total
ASIAN01000000001
BLACK OR AFRICAN AMERICAN913151614316131411124
09

Study locations

1 site
  • GSK Investigational Site
    Bellville, 7530, South Africa
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in May 2025, 34 months.

Results were first posted in Jun 2026, 1 year after primary completion.

Of 43 phase 2 interventional studies under Tuberculosis, Pulmonary, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 37. This study's 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2022
First posted
May 19, 2022
StartActual
Jul 26, 2022
Primary completionActual
May 27, 2025
CompletionActual
May 27, 2025
Results first posted
Jun 17, 2026
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT05382312
Lead sponsor
GlaxoSmithKline
Collaborators
Click-TB Consortium
Responsible party
Sponsor
First posted
May 19, 2022
Start date
Jul 26, 2022
Primary completion
May 27, 2025
Completion
May 27, 2025
Results posted
Jun 17, 2026
Last update
Jun 17, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: GSK656 · Bedaquiline · OPC-67683 · Isoniazid · Rifampin · Pyrazinamide · Ethambutol

Start the discussion